|
1
|
WHO, . Breast cancer: Prevention and
control. Retrieved October 19, 2016. http://www.who.int/cancer/detection/breastcancer/en/index1.html
|
|
2
|
Radpour R, Barekati Z, Kohler C, Lv Q,
Bürki N, Diesch C, Bitzer J, Zheng H, Schmid S and Zhong XY:
Hypermethylation of tumor suppressor genes involved in critical
regulatory pathways for developing a blood-based test in breast
cancer. PLoS One. 6:e160802011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swedish Organised Service Screening
Evaluation Group, . Reduction in breast cancer mortality from the
organised service screening with mammography: 2. Validation with
alternative analytic methods. Cancer Epidemiol Biomarkers Prev.
15:52–56. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nelson HD, O'Meara ES, Kerlikowske K,
Balch S and Miglioretti D: Factors associated with rates of
false-positive and false-negative results from digital mammography
screening: An analysis of registry data. Ann Intern Med.
164:226–235. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Njor SH, Hallas J, Schwartz W, Lynge E and
Pedersen AT: Type of hormone therapy and risk of misclassification
at mammography screening. Menopause. 18:171–177. 2011.PubMed/NCBI
|
|
6
|
Baylin SB, Belinsky SA and Herman JG:
Aberrant methylation of gene promoters in cancer-concepts,
misconcepts, and promise. J Natl Cancer Inst. 92:1460–1461. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones PA and Laird PW: Cancer epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toh Y, Egashira A and Yamamoto M:
Epigenetic alterations and their clinical implications in
esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg.
61:262–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang F, Turcan S, Rimner A, Kaufman A,
Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, et al: Breast
cancer methylomes establish an epigenomic foundation for
metastasis. Sci Transl Med. 3:75ra252011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim D Cheol, Thorat MA, Lee MR, Cho SH,
Vasiljević N, Scibior-Bentkowska D, Wu K, Ahmad AS, Duffy S, Cuzick
JM and Lorincz AT: Quantitative DNA methylation and recurrence of
breast cancer: A study of 30 candidate genes. Cancer Biomark.
11:75–88. 2012.PubMed/NCBI
|
|
12
|
Pang JM, Deb S, Takano EA, Byrne DJ, Jene
N, Boulghourjian A, Holliday A, Millar E, Lee CS, O'Toole SA, et
al: Methylation profiling of ductal carcinoma in situ and its
relationship to histopathological features. Breast Cancer Res.
16:4232014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brooks JD, Cairns P, Shore RE, Klein CB,
Wirgin I, Afanasyeva Y and Zeleniuch-Jacquotte A: DNA methylation
in pre-diagnostic serum samples of breast cancer cases: Results of
a nested case-control study. Cancer Epidemiol. 34:717–723. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fackler MJ, McVeigh M, Evron E, Garrett E,
Mehrotra J, Polyak K, Sukumar S and Argani P: DNA methylation of
RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and
invasive lobular breast carcinoma. Int J Cancer. 107:970–975. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fackler MJ, McVeigh M, Mehrotra J, Blum
MA, Lange J, Lapides A, Garrett E, Argani P and Sukumar S:
Quantitative multiplex methylation-specific PCR assay for the
detection of promoter hypermethylation in multiple genes in breast
cancer. Cancer Res. 64:4442–4452. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Terry MB, McDonald JA, Wu HC, Eng S and
Santella RM: Epigenetic biomarkers of breast cancer risk: Across
the breast cancer prevention continuum. Adv Exp Med Biol.
882:33–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brooks J, Cairns P and Zeleniuch-Jacquotte
A: Promoter methylation and the detection of breast cancer. Cancer
Causes Control. 20:1539–1550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sturgeon SR, Balasubramanian R, Schairer
C, Muss HB, Ziegler RG and Arcaro KF: Detection of promoter
methylation of tumor suppressor genes in serum DNA of breast cancer
cases and benign breast disease controls. Epigenetics. 7:1258–1267.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Singletary SE and Connolly JL: Breast
cancer staging: Working with the sixth edition of the AJCC Cancer
Staging Manual. CA Cancer J Clin. 56:37–47. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amara K, Trimeche M, Ziadi S, Laatiri A,
Hachana M, Sriha B, Mokni M and Korbi S: Presence of simian virus
40 DNA sequences in diffuse large B-cell lymphomas in Tunisia
correlates with aberrant promoter hypermethylation of multiple
tumor suppressor genes. Int J Cancer. 121:2693–2702. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baldwin RL, Nemeth E, Tran H, Shvartsman
H, Cass I, Narod S and Karlan BY: BRCA1 promoter region
hypermethylation in ovarian carcinoma: A population-based study.
Cancer Res. 60:5329–5333. 2000.PubMed/NCBI
|
|
22
|
Pongtheerat T, Pakdeethai S, Purisa W,
Chariyalertsak S and Petmitr S: Promoter methylation and genetic
polymorphism of glutathione S-transferase P1 gene (GSTP1) in Thai
breast- cancer patients. Asian Pac J Cancer Prev. 12:2731–2734.
2011.PubMed/NCBI
|
|
23
|
Vallian S, Sedaghat M, Nassiri I and
Frazmand A: Methylation status of p16 INK4A tumor suppressor gene
in Iranian patients with sporadic breast cancer. J Cancer Res Clin
Oncol. 135:991–996. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ye C, Shrubsole MJ, Cai Q, Ness R, Grady
WM, Smalley W, Cai H, Washington K and Zheng W: Promoter
methylation status of the MGMT, hMLH1, and CDKN2Ap16 genes in
non-neoplastic mucosa of patients with and without colorectal
adenomas. Oncol Rep. 16:429–435. 2006.PubMed/NCBI
|
|
25
|
Muñoz J, Inda MM, Lázcoz P, Zazpe I, Fan
X, Alfaro J, Tuñón T, Rey JA and Castresana JS: Promoter
methylation of RASSF1A associates to adult secondary glioblastomas
and pediatric glioblastomas. ISRN Neurol. 2012:5765782012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karray-Chouayekh S, Trifa F, Khabir A,
Boujelbane N, Sellami-Boudawara T, Daoud J, Frikha M, Jlidi R,
Gargouri A and Mokdad-Gargouri R: Aberrant methylation of RASSF1A
is associated with poor survival in Tunisian breast cancer
patients. J Cancer Res Clin Oncol. 136:203–210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsubayashi H, Sato N, Fukushima N, Yeo
CJ, Walter KM, Brune K, Sahin F, Hruban RH and Goggins M:
Methylation of cyclin D2 is observed frequently in pancreatic
cancer but is also an age-related phenomenon in gastrointestinal
tissues. Clin Cancer Res. 9:1446–1452. 2003.PubMed/NCBI
|
|
28
|
Bai X, Fu Y, Xue H, Guo K, Song Z, Yu Z,
Jia T, Yan Y, Zhao L, Mi X, et al: BRCA1 promoter hypermethylation
in sporadic epithelial ovarian carcinoma: Association with low
expression of BRCA1, improved survival and co-expression of DNA
methyltransferases. Oncol Lett. 7:1088–1096. 2014.PubMed/NCBI
|
|
29
|
Dworkin AM, Huang TH and Toland AE:
Epigenetic alterations in the breast: Implications for breast
cancer detection, prognosis and treatment. Semin Cancer Biol.
19:165–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen Y, Zhou J, Xu Y, Li Z, Wen X, Yao L,
Xie Y and Deng D: BRCA1 promoter methylation associated with poor
survival in Chinese patients with sporadic breast cancer. Cancer
Sci. 100:1663–1667. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shinozaki M, Hoon DS, Giuliano AE, Hansen
NM, Wang HJ, Turner R and Taback B: Distinct hypermethylation
profile of primary breast cancer is associated with sentinel lymph
node metastasis. Clin Cancer Res. 11:2156–2162. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sharma G, Mirza S, Parshad R, Srivastava
A, Gupta SD, Pandya P and Ralhan R: Clinical significance of
promoter hypermethylation of DNA repair genes in tumor and serum
DNA in invasive ductal breast carcinoma patients. Life Sci.
87:83–91. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sadeq V, Isar N and Manoochehr T:
Association of sporadic breast cancer with PTENMMAC1TEP1 promoter
hypermethylation. Med Oncol. 28:420–423. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu L, Wang F, Xu R, Zhang S, Peng X, Feng
Y, Wang J and Lu C: Promoter methylation of BRCA1 in the prognosis
of breast cancer: A meta-analysis. Breast Cancer Res Treat.
142:619–627. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shilpa V, Bhagat R, Premalata CS, Pallavi
VR, Ramesh G and Krishnamoorthy L: BRCA1 promoter hypermethylation
and protein expression in ovarian carcinoma-an Indian study. Tumour
Biol. 35:4277–4284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Esteller M, Corn PG, Urena JM, Gabrielson
E, Baylin SB and Herman JG: Inactivation of glutathione
S-transferase P1 gene by promoter hypermethylation in human
neoplasia. Cancer Res. 58:4515–4518. 1998.PubMed/NCBI
|
|
37
|
Ronneberg JA, Tost J, Solvang HK, Alnaes
GI, Johansen FE, Brendeford EM, Yakhini Z, Gut IG, Lønning PE,
Børresen-Dale AL, et al: GSTP1 promoter haplotypes affect DNA
methylation levels and promoter activity in breast carcinomas.
Cancer Res. 68:5562–5571. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee JJ, Ko E, Cho J, Park HY, Lee JE, Nam
SJ, Kim DH and Cho EY: Methylation and immunoexpression of p16
(INK4a) tumor suppressor gene in primary breast cancer tissue and
their quantitative p16 (INK4a) hypermethylation in plasma by
real-time PCR. Korean J Pathol. 46:554–561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Johnson KC, Koestler DC, Cheng C and
Christensen BC: Age-related DNA methylation in normal breast tissue
and its relationship with invasive breast tumor methylation.
Epigenetics. 9:268–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang J, Pickering CR, Holst CR, Gauthier
ML and Tlsty TD: p16INK4a modulates p53 in primary human mammary
epithelial cells. Cancer Res. 66:10325–10331. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Radpour R, Barekati Z, Haghighi MM, Kohler
C, Asadollahi R, Torbati PM, Holzgreve W and Zhong XY: Correlation
of telomere length shortening with promoter methylation profile of
p16Rb and p53p21 pathways in breast cancer. Mod Pathol. 23:763–772.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ingold B, Schraml P, Heppner FL and Moch
H: Homogeneous MGMT immunoreactivity correlates with an
unmethylated MGMT promoter status in brain metastases of various
solid tumors. PLoS One. 4:e47752009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Asiaf A, Ahmad ST, Malik AA, Aziz SA,
Rasool Z, Masood A and Zargar MA: Protein expression and
methylation of MGMT, a DNA repair gene and their correlation with
clinicopathological parameters in invasive ductal carcinoma of the
breast. Tumour Biol. 36:6485–6496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sharma G, Mirza S, Prasad CP, Srivastava
A, Gupta SD and Ralhan R: Promoter hypermethylation of p16INK4A,
p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast
cancer patients. Life Sci. 80:1873–1881. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pu RT, Laitala LE, Alli PM, Fackler MJ,
Sukumar S and Clark DP: Methylation profiling of benign and
malignant breast lesions and its application to cytopathology. Mod
Pathol. 16:1095–1101. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang HY, Liang F, Jia ZL, Song ST and
Jiang ZF: Mutation, methylation and expression in breast cancer
patients. Oncol Lett. 6:161–168. 2013.PubMed/NCBI
|
|
47
|
Kim Y, Jin D, Lee BB, Cho EY, Han J, Shim
YM and Kim DH: RARbeta2 hypermethylation is associated with poor
recurrence-free survival in never-smokers with adenocarcinoma of
the lung. Clinical Epigenetics. 7:322015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tao MH, Shields PG, Nie J, Millen A,
Ambrosone CB, Edge SB, Krishnan SS, Marian C, Xie B, Winston J, et
al: DNA hypermethylation and clinicopathological features in breast
cancer: The Western New York exposures and breast cancer (WEB)
study. Breast Cancer Res Treat. 114:559–568. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee X, Si SP, Tsou HC and Peacocke M:
Cellular aging and transformation suppression: A role for retinoic
acid receptor beta 2. Exp Cell Res. 218:296–304. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dulaimi E, Hillinck J, de Caceres I
Ibanez, Al-Saleem T and Cairns P: Tumor suppressor gene promoter
hypermethylation in serum of breast cancer patients. Clin Cancer
Res. 10:6189–6193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cowin P, Rowlands TM and Hatsell SJ:
Cadherins and catenins in breast cancer. Curr Opin Cell Biol.
17:499–508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Falahi F, Sgro A and Blancafort P:
Epigenome engineering in cancer: Fairytale or a realistic path to
the clinic? Front Oncol. 5:222015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Connolly R and Stearns V: Epigenetics as a
therapeutic target in breast cancer. J Mammary Gland Biol
Neoplasia. 17:191–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
